MCID: MCS002
MIFTS: 54

Mucositis

Categories: Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Mucositis

MalaCards integrated aliases for Mucositis:

Name: Mucositis 11 53 43 14 16 75
Inflammatory Disease of Mucous Membrane 71
Gastrointestinal Mucositis 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0080178
MeSH 43 D052016
UMLS 71 C0333355 C0521585

Summaries for Mucositis

Disease Ontology: 11 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary: Mucositis, also known as inflammatory disease of mucous membrane, is related to common cold and diarrhea, and has symptoms including oral manifestations, signs and symptoms, digestive and catarrh. An important gene associated with Mucositis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Ethanol and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia: 75 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Related Diseases for Mucositis

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 587)
# Related Disease Score Top Affiliating Genes
1 common cold 32.1 IL1B IL10 CSF2
2 diarrhea 31.4 TLR4 IL1B IL10 CSF3 ABCB1
3 exanthem 31.2 VEGFA MTOR IL1B IL10 CSF3 CSF2
4 leukemia, acute lymphoblastic 31.2 TYMS MTHFR CSF3 CSF2 ABCB1
5 gingivitis 31.0 VEGFA IL1B IL10 CSF3
6 stomatitis 31.0 MTOR IL1B IL10 FGF7 DPYD CSF3
7 candidiasis 31.0 TLR4 IL1B IL10 CSF3 CSF2
8 aphthous stomatitis 30.9 IL1B IL10 CSF3
9 acute leukemia 30.8 MTHFR CSF3 CSF2 ABCB1
10 hematologic cancer 30.8 VEGFA MTOR IL11 FGF7 CSF3 CSF2
11 neutropenia 30.8 TYMS IL1B IL11 IL10 DPYD CSF3
12 childhood acute lymphocytic leukemia 30.8 XRCC1 TYMS MTHFR ABCB1
13 proteasome-associated autoinflammatory syndrome 1 30.7 TLR4 IL1B IL10
14 squamous cell carcinoma 30.6 XRCC1 VEGFA NFE2L2 MTOR EGF CD44
15 acute graft versus host disease 30.6 IL10 CSF3
16 pneumonia 30.6 TLR4 IL1B IL10 CSF3 CSF2
17 osteonecrosis 30.6 VEGFA MTHFR IL10 ABCB1
18 chlamydia 30.5 TLR4 IL1B IL10 CSF2
19 squamous cell carcinoma, head and neck 30.5 VEGFA TYMS NFE2L2 EGF DPYD CSF2
20 otitis media 30.5 TLR4 IL1B IL10 CSF3
21 granulocytopenia 30.5 CSF3 CSF2
22 crohn's disease 30.5 TLR9 TLR4 IL1B IL10 CSF2
23 viral infectious disease 30.4 TLR9 TLR4 IL1B IL10
24 esophageal cancer 30.4 VEGFA TYMS MTOR IL1B IL10 EGF
25 myeloma, multiple 30.4 VEGFA MTOR IL1B IL11 CSF3 CSF2
26 aplastic anemia 30.4 IL1B IL11 IL10 CSF3 CSF2
27 mucormycosis 30.3 IL10 CSF3 CSF2
28 peritonitis 30.3 TLR4 IL1B IL10 CSF3
29 leishmaniasis 30.3 TLR9 TLR4 IL1B IL10
30 hepatic veno-occlusive disease 30.3 VEGFA CSF3 ABCB1
31 irritable bowel syndrome 30.3 TLR4 IL1B IL10
32 inflammatory bowel disease 1 30.3 TLR4 IL1B IL10
33 toxic shock syndrome 30.2 TLR4 IL1B IL10 CSF3
34 invasive aspergillosis 30.2 TLR9 TLR4 IL10 CSF3
35 respiratory failure 30.2 VEGFA TLR4 IL1B IL10 FGF7 CSF3
36 toxic encephalopathy 30.2 TLR4 NFE2L2 IL1B IL10
37 burkitt lymphoma 30.2 XRCC1 TLR9 IL10 CSF3 CD44
38 aggressive periodontitis 30.2 TLR4 IL1B IL10
39 aspergillosis 30.2 TLR9 TLR4 IL1B IL10 CSF3 CSF2
40 cystitis 30.2 VEGFA TLR4 EGF
41 kidney cancer 30.2 VEGFA MTOR EGF CD44 ABCB1
42 contact dermatitis 30.1 IL1B IL10 CSF2
43 disease by infectious agent 30.1 TLR9 TLR4 IL1B IL10
44 gingival overgrowth 30.1 IL10 FGF7 EGF ABCB1
45 urethritis 30.1 TLR4 IL1B IL10
46 ileus 30.1 IL1B IL10 CSF2
47 leukemia, acute myeloid 30.1 VEGFA MTOR IL1B IL10 EGF CSF3
48 plague 30.0 TLR4 IL1B IL10
49 urinary tract infection 30.0 TLR4 IL1B IL10
50 chronic mucocutaneous candidiasis 30.0 IL1B IL10 CSF2

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis

Symptoms & Phenotypes for Mucositis

UMLS symptoms related to Mucositis:


oral manifestations; signs and symptoms, digestive; catarrh

GenomeRNAi Phenotypes related to Mucositis according to GeneCards Suite gene sharing:

25 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.33 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.33 IL10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.33 NFE2L2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.33 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.33 TLR4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.33 NFE2L2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.33 NFE2L2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.33 IL10 NFE2L2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.33 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.33 MTHFR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.33 MTHFR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.33 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.33 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.33 IL10 MTHFR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.33 TLR4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.33 NFE2L2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.33 MTHFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.33 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.33 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-58 10.33 NFE2L2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.33 MTHFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.33 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.33 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.33 IL10 TLR4
25 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.33 MTHFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.33 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.33 IL10
28 no effect GR00402-S-1 10.15 ABCB1 CSF2 CSF3 DPYD EGF FGF7
29 no effect GR00402-S-2 10.15 CD44 CSF2 CSF3 DPYD EGF FGF7
30 Reduced mammosphere formation GR00396-S 9.5 CD44 CSF3 MTOR NFE2L2 TLR9 TYMS

MGI Mouse Phenotypes related to Mucositis:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.39 ABCB1 CD44 CSF2 FGF7 IL10 IL1B
2 homeostasis/metabolism MP:0005376 10.39 ABCB1 CD44 CSF2 FGF7 IL10 IL1B
3 growth/size/body region MP:0005378 10.34 ABCB1 CD44 CSF2 EGF IL10 IL1B
4 immune system MP:0005387 10.28 ABCB1 CD44 CSF2 CSF3 EGF FGF7
5 behavior/neurological MP:0005386 10.25 ABCB1 CD44 CSF2 DPYD FGF7 IL10
6 renal/urinary system MP:0005367 10.24 CD44 CSF2 CSF3 FGF7 MTOR NFE2L2
7 normal MP:0002873 10.21 CD44 EGF IL10 MTOR NFE2L2 TGFB3
8 endocrine/exocrine gland MP:0005379 10.18 ABCB1 CD44 CSF2 EGF IL10 MTOR
9 neoplasm MP:0002006 10.17 CD44 CSF2 IL10 IL1B NFE2L2 TLR4
10 digestive/alimentary MP:0005381 10.16 ABCB1 CD44 DPYD EGF IL10 NFE2L2
11 limbs/digits/tail MP:0005371 10.13 CD44 FGF7 IL10 MTHFR NFE2L2 TGFB3
12 reproductive system MP:0005389 10.13 ABCB1 CD44 CSF2 DPYD EGF FGF7
13 skeleton MP:0005390 10 CD44 CSF2 IL10 IL1B MTHFR MTOR
14 hematopoietic system MP:0005397 10 ABCB1 CD44 CSF2 CSF3 FGF7 IL10
15 respiratory system MP:0005388 9.97 CD44 CSF2 IL10 MTOR NFE2L2 TGFB3
16 mortality/aging MP:0010768 9.8 ABCB1 CD44 CSF2 IL10 IL1B MTHFR
17 integument MP:0010771 9.4 CD44 CSF2 CSF3 EGF FGF7 IL10

Drugs & Therapeutics for Mucositis

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 343)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
3
Hexetidine Approved, Investigational Phase 4 141-94-6 3607
4
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
5
Ofloxacin Approved Phase 4 82419-36-1 4583
6
Copper Approved, Investigational Phase 4 7440-50-8 27099
7
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
8
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109
9
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 10631 6279
10
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
13
Promethazine Approved, Investigational Phase 4 60-87-7 4927
14
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
15
Povidone K30 Approved, Experimental Phase 4 9003-39-8 6917 131751496
16
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
17
Simethicone Approved Phase 4 8050-81-5
18
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
19
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
20
Lipoic acid Approved, Investigational, Nutraceutical Phase 4 1077-27-6, 1200-22-2 864 445125 6112
21
Diethyl ether Experimental Phase 4 60-29-7 3283
22 Gastrointestinal Agents Phase 4
23 Antiprotozoal Agents Phase 4
24 Antiparasitic Agents Phase 4
25 Cola Phase 4
26 Picosulfate sodium Phase 4
27 Cathartics Phase 4
28 Laxatives Phase 4
29 Micronutrients Phase 4
30 Trace Elements Phase 4
31 Cytochrome P-450 Enzyme Inhibitors Phase 4
32 Antineoplastic Agents, Hormonal Phase 4
33 Copper Supplement Phase 4
34 Contraceptives, Oral, Hormonal Phase 4
35 Contraceptives, Oral Phase 4
36 Contraceptive Agents, Male Phase 4
37 Contraceptive Agents Phase 4
38 Dermatologic Agents Phase 4
39 Chlorhexidine gluconate Phase 4
40 Anti-Infective Agents, Local Phase 4
41 Disinfectants Phase 4
42 Alpha-lipoic Acid Phase 4
43 Immunologic Factors Phase 4
44 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
45 Blood Substitutes Phase 4
46 Plasma Substitutes Phase 4
47 Adjuvants, Immunologic Phase 4
48 Viscosupplements Phase 4
49
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
50
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778

Interventional clinical trials:

(show top 50) (show all 392)
# Name Status NCT ID Phase Drugs
1 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
2 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
3 A Comparison of Oral Controlled-release Morphine With Transdermal Fentanyl in Nasopharyngeal Cancer Patients With Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy Unknown status NCT04292990 Phase 4 Fentanyl;Morphine
4 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
5 Pilot Study: The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Peri-implant Mucositis Completed NCT04838054 Phase 4 Stabilized chlorine dioxide oral rinse
6 The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis. Completed NCT02023853 Phase 4 metronidazole gel
7 Clinical and Microbiological Evaluation of the Effect of Probiotic Lactobacillus Reuteri Prodentis in the Treatment of Mucositis and Periimplantitis Completed NCT03047291 Phase 4 Probiotic
8 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
9 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash
10 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
11 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
12 Impact of Oral Hygiene Gels on Peri-implant Mucositis Completed NCT03243591 Phase 4
13 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
15 Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC) Recruiting NCT05055726 Phase 4 Benzydamine Hydrochloride 0.15% w/v oromucosal solution
16 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin Injection;Compound Kushen Injection(CKI)
17 The UMPALA Study: A Clinical Study to Assess the Impact of Contraceptives on the Cervico-Vaginal Mucosa Recruiting NCT04814927 Phase 4 Copper IUD;Etonogestrel implant;Levonorgestrel IUS;DMPA Sub-cutaneous
18 OZOCLO: a Randomized Clinical Trial for Prevention of Oral Mucositis Not yet recruiting NCT05211622 Phase 4 1. alpha acid lipoic - tables;2. ozonated oil - mouthwash;3. chlorhexidine 0,2% - mouthwash;4. sodium bicarbonate 5% solution - mouthwash
19 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
20 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Withdrawn NCT01288625 Phase 4 Amifostine
21 Evaluation of Low-energy Laser Therapy for Prevention and Reduction of Severity of Oral Mucositis in Children "Mucositis Laser 1" Unknown status NCT01007617 Phase 2, Phase 3
22 A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02085694 Phase 2, Phase 3 Lactobacillus brevis CD2
23 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
24 A Randomized Trial to Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Unknown status NCT04080622 Phase 3 Selenium;Placebos
25 The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial Unknown status NCT02282839 Phase 3
26 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
27 Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial Unknown status NCT02313792 Phase 3 Palifermin
28 Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults Unknown status NCT02173756 Phase 3 morphine gel;placebo gel
29 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
30 The Clinical Study for Evaluation of Efficacy and Safety of EGF on Oral Mucositis in Radiation Therapy Patients Unknown status NCT01099891 Phase 3 rhEGF;Placebo
31 A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
32 Management of Mucositis With GM-CSF (Sargramostim) Mouthwash Study Protocol Completed NCT00293462 Phase 3
33 Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers. Completed NCT02868151 Phase 2, Phase 3 Ascorbic Acid;Zinc acetate
34 Clinical Effect of Probiotic Use Bifidobacterium Animalis Subsp. Lactis as Adjunctive Therapy in Non-surgical Treatment of Periimplant Mucositis: a Randomized Controlled Trial Completed NCT04187222 Phase 3
35 Evaluate Safety and Tolerability and Compare Absorption/Distribution Kinetics of a Single 100 Mcg Dose of Fentanyl Sublingual Spray (Fentanyl SL Spray) in Cancer Subjects With or Without Oral Mucositis Completed NCT00956254 Phase 3 Fentanyl sublingual spray
36 To Access the Effects of Mucositis in Adults With Dental Implants Completed NCT01072201 Phase 3 Triclosan and Fluoride;Fluoride
37 Prevention High Dose Chemotherapy Induced Mucositis by Using Zinc Sulfate Completed NCT01015183 Phase 2, Phase 3 Zinc Sulfate;Placebo
38 A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer Completed NCT00615420 Phase 3
39 Randomized Cross-over Study of Curcumin for Prevention of Oral Mucositis in Children Receiving Doxorubicin Based Chemotherapy. Completed NCT00475683 Phase 3
40 Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT) Completed NCT00101582 Phase 3 Placebo;palifermin;cisplatin chemotherapy
41 A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Completed NCT00814359 Phase 3 Combination of Magic Mouthwash Plus Sucralfate;0.15% Benzydamine HCl
42 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Assess the Efficacy and Safety of SBG on Oral Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT00790322 Phase 3 SBG
43 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
44 Use of Topical Non-Steroidal Anti- Inflammatory to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions. Completed NCT03509675 Phase 2, Phase 3 Ibuprofen suspension 5mg/100ml;Placebos
45 Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial Completed NCT02555501 Phase 3
46 A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
47 A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation Completed NCT02480114 Phase 3 Gabapentin;Oxycodone/Acetaminophen;Hydrocodone/Acetaminophen;Fentanyl;Ibuprofen;Magic Mouthwash
48 A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck Completed NCT03237325 Phase 3 SGX942;Placebo
49 Phase III Randomized Double-blind Cross-over Trial of Caphosol® Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy Completed NCT01265810 Phase 3
50 Phase III Trial of Low-level Laser Therapy to Prevent Induced Oral Mucositis in Head and Neck Cancer Patients Submitted to Concurrent Chemoradiation Completed NCT01439724 Phase 3

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Genetic Tests for Mucositis

Anatomical Context for Mucositis

Organs/tissues related to Mucositis:

MalaCards : Bone Marrow, Breast, Bone, Lung, Colon, Myeloid, Salivary Gland

Publications for Mucositis

Articles related to Mucositis:

(show top 50) (show all 11172)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 53 62
20336592 2010
2
Keratinocyte growth factor. 53 62
19456212 2009
3
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. 53 62
18829546 2008
4
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. 53 62
18560408 2008
5
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. 53 62
18197435 2008
6
Cytokines following SCT: indications and controversies. 53 62
18545239 2008
7
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. 53 62
18299612 2008
8
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 53 62
17165084 2007
9
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. 53 62
18632516 2007
10
Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. 53 62
17728847 2007
11
Head and neck radiation and mucositis. 53 62
18660721 2007
12
Interventions for treating oral mucositis for patients with cancer receiving treatment. 53 62
17443514 2007
13
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. 53 62
17293228 2007
14
Cancer treatment-induced oral mucositis. 53 62
17465250 2007
15
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. 53 62
17059384 2006
16
A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. 53 62
16904525 2006
17
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. 53 62
16965690 2006
18
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. 53 62
16912178 2006
19
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. 53 62
16803675 2006
20
Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. 53 62
16634706 2006
21
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. 53 62
16414253 2006
22
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. 53 62
16537186 2006
23
R-Spondin proteins: a novel link to beta-catenin activation. 53 62
16357527 2006
24
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. 53 62
16322806 2005
25
Mucosal protection by cytokines. 53 62
16232381 2005
26
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. 53 62
15683818 2005
27
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. 53 62
16110136 2005
28
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. 53 62
15623608 2004
29
Interventions for treating oral mucositis for patients with cancer receiving treatment. 53 62
15106165 2004
30
Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. 53 62
12649101 2003
31
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. 53 62
12697866 2003
32
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. 53 62
12759532 2003
33
Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. 53 62
12243825 2002
34
The effects of keratinocyte growth factor in preclinical models of mucositis. 53 62
12139710 2002
35
Are Central Eastern European countries involved in clinical trials of supportive care? 53 62
12029429 2002
36
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. 53 62
11919725 2002
37
Biological actions and therapeutic potential of the glucagon-like peptides. 53 62
11832466 2002
38
Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. 53 62
11597377 2001
39
Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. 53 62
11545238 2001
40
Genomics and drug discovery. 53 62
11511852 2001
41
Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 53 62
11503611 2001
42
Repifermin. Human Genome Sciences/GlaxoSmithKline. 53 62
15995938 2001
43
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. 53 62
11313683 2001
44
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. 53 62
11212269 2001
45
Prevention and management of mucositis in patients with cancer. 53 62
11053801 2000
46
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. 53 62
10899677 2000
47
Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 53 62
10701730 2000
48
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. 53 62
10578158 1999
49
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 53 62
10473079 1999
50
The biological basis for the attenuation of mucositis: the example of interleukin-11. 53 62
10360368 1999

Variations for Mucositis

Expression for Mucositis

Search GEO for disease gene expression data for Mucositis.

Pathways for Mucositis

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 VEGFA TLR9 TLR4 MTOR IL1B IL11
2
Show member pathways
13.77 EGF FGF7 IL10 IL1B MTOR NFE2L2
3
Show member pathways
13.75 VEGFA TGFB3 MTOR IL1B IL11 IL10
4
Show member pathways
13.57 VEGFA TLR4 TGFB3 MTOR IL1B IL11
5
Show member pathways
13.49 VEGFA TGFB3 MTOR IL1B IL11 IL10
6
Show member pathways
13.26 CD44 CSF2 CSF3 IL10 IL11 IL1B
7
Show member pathways
13.23 CSF2 CSF3 EGF FGF7 IL10 IL11
8
Show member pathways
13.14 CSF2 CSF3 EGF FGF7 IL10 IL11
9
Show member pathways
12.9 VEGFA TLR4 MTOR FGF7 EGF CSF3
10 12.78 VEGFA TLR9 MTOR FGF7 EGF
11
Show member pathways
12.61 TLR9 TLR4 TGFB3 IL1B FGF7 EGF
12
Show member pathways
12.58 EGF FGF7 IL10 IL1B MTOR TGFB3
13
Show member pathways
12.37 TLR9 TLR4 IL1B IL11
14 12.35 EGF FGF7 IL1B TGFB3
15 12.09 EGF TGFB3 TLR4 TLR9 VEGFA
16 12.02 VEGFA IL11 FGF7 EGF
17 11.89 VEGFA MTOR IL1B IL10 FGF7 EGF
18 11.87 VEGFA TLR9 NFE2L2
19
Show member pathways
11.87 TLR9 TLR4 IL1B IL10
20 11.87 IL11 IL10 CSF3 CSF2 CD44
21 11.85 VEGFA MTOR IL10
22 11.85 TGFB3 EGF CD44
23
Show member pathways
11.83 TLR4 CSF3 CSF2
24 11.82 VEGFA IL1B IL10 ABCB1
25
Show member pathways
11.8 TLR9 TLR4 TGFB3 IL1B
26 11.79 VEGFA TGFB3 MTOR
27 11.75 IL1B IL10 CD44
28 11.74 VEGFA EGF CD44
29 11.69 VEGFA NFE2L2 MTOR
30
Show member pathways
11.69 TYMS MTHFR DPYD
31 11.66 TLR9 IL1B IL10 CSF2
32
Show member pathways
11.62 VEGFA IL1B CSF2
33 11.61 TLR4 IL1B IL10
34 11.59 VEGFA TLR4 TGFB3 IL1B EGF
35 11.53 VEGFA TGFB3 EGF
36 11.44 VEGFA TGFB3 IL11 EGF
37 11.43 VEGFA FGF7 EGF
38 11.41 IL1B IL10 CSF3 CSF2
39
Show member pathways
11.34 TGFB3 IL10 CSF2
40 11.3 TLR4 IL1B IL10
41 11.23 NFE2L2 IL1B FGF7 EGF CSF3 CSF2
42 11.02 TLR4 IL1B IL10
43 11.02 IL1B IL11 IL10 CSF3 CSF2
44 10.87 TGFB3 IL1B IL11 IL10 FGF7 EGF
45 10.77 IL1B TGFB3
46 10.72 TLR4 MTOR
47 10.67 TYMS MTHFR

GO Terms for Mucositis

Cellular components related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.66 VEGFA TLR9 TGFB3 RSPO1 IL1B IL11

Biological processes related to Mucositis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.5 CSF3 IL10 IL11 IL1B NFE2L2 TGFB3
2 inflammatory response GO:0006954 10.3 TLR9 TLR4 NFE2L2 MTOR IL1B CD44
3 immune response GO:0006955 10.29 TLR9 TLR4 IL1B IL10 CSF3 CSF2
4 positive regulation of protein phosphorylation GO:0001934 10.19 VEGFA RSPO1 MTOR IL1B FGF7
5 positive regulation of cell population proliferation GO:0008284 10.16 CSF2 CSF3 EGF FGF7 IL11 IL1B
6 response to xenobiotic stimulus GO:0009410 10.11 ABCB1 IL10 MTHFR NFE2L2 TYMS XRCC1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.1 VEGFA IL11 CSF3 CD44
8 positive regulation of epithelial to mesenchymal transition GO:0010718 10.09 TGFB3 MTOR IL1B
9 positive regulation of MAPK cascade GO:0043410 10.09 VEGFA TLR9 TGFB3 IL11 EGF
10 positive regulation of MAP kinase activity GO:0043406 10.08 VEGFA TLR4 IL1B EGF
11 positive regulation of endothelial cell proliferation GO:0001938 10.06 EGF FGF7 IL10 VEGFA
12 positive regulation of chemokine production GO:0032722 10 TLR9 TLR4 IL1B
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.97 NFE2L2 IL11 IL10
14 cellular response to lipopolysaccharide GO:0071222 9.93 TLR9 TLR4 IL1B IL10 CSF3 CSF2
15 voluntary musculoskeletal movement GO:0050882 9.92 XRCC1 MTOR
16 positive regulation of cell division GO:0051781 9.92 VEGFA TGFB3 IL1B FGF7
17 positive regulation of gene expression GO:0010628 9.91 CSF2 EGF FGF7 IL1B MTOR NFE2L2
18 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.88 NFE2L2 VEGFA
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.88 IL1B IL10 CD44
20 regulation of dendritic cell cytokine production GO:0002730 9.83 TLR4 TLR9
21 monocyte aggregation GO:0070487 9.81 CD44 IL1B
22 positive regulation of epithelial tube formation GO:1905278 9.75 VEGFA EGF
23 regulation of complement-dependent cytotoxicity GO:1903659 9.6 IL11 IL10
24 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.44 VEGFA MTOR IL11 FGF7 EGF CSF3

Molecular functions related to Mucositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.8 VEGFA TGFB3 IL1B IL11 IL10 CSF3
2 growth factor activity GO:0008083 9.53 VEGFA TGFB3 IL11 IL10 FGF7 EGF

Sources for Mucositis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....